Analysts, investors and partner Summit Therapeutics had all been keenly awaiting the overall survival update, after previous ...
Drugmakers including BioNTech, Merck & Co. and Pfizer are all testing their investigational PD-1/VEGF bispecifics against ...
Risk of non-small cell lung cancer (NSCLC), a malignancy that develops in the tissues of the lung, increases considerably ...
SurvivorNet on MSN
New lung cancer drug, Ivonescimab, showed promising results in major HARMONi-6 trial, but US patients will need to wait for HARMONi-3 update
A new drug called ivonescimab just beat standard immunotherapy in a major lung cancer trial: patients lived nearly four ...
9don MSN
A hotly debated lung cancer drug cut the risk of death by 34% in a late-stage trial in China
An experimental lung cancer drug from Akeso and Summit Therapeutics reduced the risk of death by 34% in a late-stage trial, ...
Mechanistic insights into how B7x-mediated immune evasion drives resistance to PD-1/PD-L1 blockade in bladder cancer ...
PD-(L)1×VEGF bispecifics have emerged as a closely watched new class in immuno-oncology, with multiple candidates advancing ...
PD-1 checkpoint proteins on T cells (blue) can bind to two different receptors: PD-L1 and PD-L2. There are many ways to climb a mountain. This saying especially rings true in cancer research, where ...
Immunotherapy wipes out some colorectal tumors without surgery, signaling a major shift toward less invasive treatment.
It’s the moment of truth for Akeso’s ivonescimab, and to many, a high-stakes test for China’s booming biotech industry. | ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results